Exvastat Banner

Exvastat is an innovative, clinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The new treatment has the potential to significantly reduce the high mortality and incapacitating morbidities caused by ARDS, as well as the costs of caring for these critically ill patients to health service providers. ARDS currently lacks any approved pharmaceutical therapy, with treatment limited to supportive ventilatory care.